Industry Trends and Global Forecasts, Till 2035" report has been added to ResearchAndMarkets.com's offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to ...
Data from a comparative study found liraglutide and dulaglutide presented similar effectiveness as semaglutide in the ...
In a large randomized trial involving patients with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide in reducing major cardiovascular ...
James Chen, CMT is an expert trader, investment adviser, and global market strategist. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, ...
Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Robert Kelly is managing director of ...
The SURPASS-CVOT trial—the large cardiovascular outcomes study that showed tirzepatide (Mounjaro) compared favorably with dulaglutide (Trulicity; both Eli Lilly) in patients with type 2 diabetes and ...
Tirzepatide was noninferior to dulaglutide in reducing a composite of cardiovascular events in people with type 2 diabetes and existing heart disease. Both agents are currently approved for type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback